<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956822</url>
  </required_header>
  <id_info>
    <org_study_id>M2018223</org_study_id>
    <nct_id>NCT04956822</nct_id>
  </id_info>
  <brief_title>Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases</brief_title>
  <official_title>Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a cross-sectional study in which patients were divided into 20 patients with&#xD;
      amyotrophic lateral sclerosis, 20 patients with peroneal muscular dystrophy, 20 patients with&#xD;
      Kennedy's disease and 30 healthy controls, in which patients with amyotrophic lateral&#xD;
      sclerosis continued to be followed up for 1 year and the results of 4 cross-sectional&#xD;
      examinations were taken.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that usually&#xD;
      starts in middle age and manifests mainly as progressive atrophy and weakness of skeletal&#xD;
      muscles throughout the body, with death from respiratory muscle involvement after 3 to 5&#xD;
      years. There are no biomarkers for early diagnosis and no effective treatments. Because of&#xD;
      the rapid progression of amyotrophic lateral sclerosis, it is important to find indicators&#xD;
      that can objectively reflect early changes in the disease. The motor unit number index&#xD;
      (MUNIX) is a non-invasive, rapid and objective method to assess the number of motor units,&#xD;
      which reflects the loss of motor neurons and has its theoretical basis in monitoring early&#xD;
      disease progression.&#xD;
&#xD;
      Objective To explore the diagnostic value of MUNIX in motor neuron disease and other related&#xD;
      disorders.&#xD;
&#xD;
      To investigate the role of the 1-year rate of change of MUNIX in monitoring the disease&#xD;
      progression in patients with amyotrophic lateral sclerosis.&#xD;
&#xD;
      To investigate the role of MUNIX in predicting survival analysis of ALS patients&#xD;
&#xD;
      [Design] This was a cross-sectional study in which patients were divided into 20 patients&#xD;
      with amyotrophic lateral sclerosis, 20 patients with peroneal muscular dystrophy, 20 patients&#xD;
      with Kennedy's disease and 30 healthy controls, in which patients with amyotrophic lateral&#xD;
      sclerosis continued to be followed up for 1 year and the results of 4 cross-sectional&#xD;
      examinations were taken.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of motor unit</measure>
    <time_frame>1 year</time_frame>
    <description>Motor unit estimation index (MUNIX) is a non-invasive electrophysiological technique that uses compound muscle action potential (CMAP) and surface electromyographic interference pattern (SIP) methods to evaluate the number of motor units (Mus) (motor unit number size, MUSIX).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The size of motor unit</measure>
    <time_frame>1 year</time_frame>
    <description>Motor unit estimation index (MUNIX) is a non-invasive electrophysiological technique that uses compound muscle action potential (CMAP) and surface electromyographic interference pattern (SIP) methods to evaluate the number and size of motor units (Mus) (motor unit number size, MUSIX).</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALS</arm_group_label>
    <description>Amyotrophic lateral sclerosis group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMT</arm_group_label>
    <description>peroneal muscular dystrophy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KD</arm_group_label>
    <description>Kennedy's disease group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Basic information</intervention_name>
    <description>Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.</description>
    <arm_group_label>ALS</arm_group_label>
    <arm_group_label>CMT</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>KD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional scores</intervention_name>
    <description>depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores</description>
    <arm_group_label>ALS</arm_group_label>
    <arm_group_label>CMT</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>KD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MINUX</intervention_name>
    <description>MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.</description>
    <arm_group_label>ALS</arm_group_label>
    <arm_group_label>CMT</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>KD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ALS is a degenerative disease of the nervous system, with an incidence of 2-3 in 100,000.&#xD;
        It usually begins in middle age and mainly presents with progressive atrophy and weakness&#xD;
        of skeletal muscles throughout the body. After 3 to 5 years, it dies of respiratory muscle&#xD;
        involvement. At present, there are no biomarkers for early diagnosis and no effective&#xD;
        treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALS patient group: 20 patients with confirmed or proposed ALS meeting the 1998 revised&#xD;
             El Escorial diagnostic criteria for limb onset ALS.&#xD;
&#xD;
          -  CMT group: 20 patients with peroneal muscular dystrophy meeting the genetically&#xD;
             confirmed diagnosis, who signed an informed consent form.&#xD;
&#xD;
          -  KD group: 20 patients with genetically confirmed Kennedy's disease consistent with&#xD;
             genetic diagnosis, signed informed consent.&#xD;
&#xD;
          -  healthy controls:&#xD;
&#xD;
               1. age-matched healthy adults who volunteered to participate;&#xD;
&#xD;
               2. definite exclusion of tremor, tonicity, and prior brain disease;&#xD;
&#xD;
               3. exclusion of common disorders affecting peripheral nerves such as entrapment&#xD;
                  peripheral neuropathy, diabetic peripheral neuropathy, and alcoholic peripheral&#xD;
                  neuropathy;&#xD;
&#xD;
               4. signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. signs of sensory impairment;&#xD;
&#xD;
          2. significant sphincter dysfunction;&#xD;
&#xD;
          3. visual and oculomotor impairment;&#xD;
&#xD;
          4. autonomic dysfunction;&#xD;
&#xD;
          5. signs of extravertebral symptoms;&#xD;
&#xD;
          6. severe cortical dysfunction;&#xD;
&#xD;
          7. ALS-like syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoxuan Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoxuan Liu</last_name>
    <phone>13910982101</phone>
    <email>zhangys0317@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoxuan Liu</last_name>
    <email>zhangys0317@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoxuan Liu</last_name>
      <phone>13910982101</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

